Search Results

You are looking at 221 - 230 of 2,880 items for :

  • Refine by Access: All x
Clear All
Full access

CLO22-035: Treatment Outcome of Ruxolitinib and Decitabine Combination Chemotherapy Among Transplant Ineligible Advanced Stage Myeloproliferative Neoplasm: A Meta-analysis

Jacqueline Agustin and Ma. Rosario Irene D. Castillo

not eligible for transplant, hence chemotherapy is a frequently chosen alternative. This meta-analysis sheds light on treatment outcomes of advanced stage myeloproliferative neoplasm patients treated with combination decitabine and ruxolitinib

Full access

HSR24-143: Impact of Frailty on Hospital Outcomes Among Patients With Hemophagocytic Lymphohistiocytosis Who Received Autologous Stem Cell Transplantation in the United States

Michael Imeh, Ani Gvajaia, Chukwunonye Amaeshi, Chiamaka Nwachukwu, and Fidelis Uwumiro

Background/Objectives: This study assessed the impact of frailty on hospital outcomes in patients with Hemophagocytic lymphohistiocytosis (HLH) who had autologous stem cell transplantation (ASCT), with the goal of improving outcomes of post

Full access

CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data

Abdenour Nabid, Nathalie Carrier, Eric Vigneault, André-Guy Martin, Thu Van Nguyen, Jean-Paul Bahary, Peter Vavassis, Marc-André Brassard, Sylvie Vass, Boris Bahoric, Robert Archambault, Francois Vincent, Redouane Bettahar, Marie Duclos, Derek Wilke, and Luis Souhami

Purpose/Objective(s): To compare the magnitude of differences in outcomes between intermediate and high risk prostate cancer (IRPC – HRPC) using NCCN classification in two concurrent phase III trials performed in the same population. Materials

Full access

HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting

Yu-Jing Huang, Paula D. Ryan, Gregory L. Price, Gebra Cuyun Carter, Kristin M. Sheffield, Emily Nash Smyth, Claudia Morato Guimaraes, Sarah Rybowski, Jonathan Rajkumar, and Lavanya Sudharshan

) patients (pts). This study examined real-world pt characteristics, select adverse events (AEs), and related outcomes of these pts. Methods: Female pts in the United States Oncology Network’s iKnowMedTM electronic health records (EHR) database were

Full access

EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review

Brenda Santellano, Rashi Agrawal, Gabriela Duchesne, Muhannad Sharara, E. Andrew Balas, Gagan Agrawal, Meng-Han Tsai, Asha Nayak-Kapoor, and Jorge E. Cortes

Background: The influence of social determinants of health (SDOH) on gastrointestinal (GI) cancer outcomes has long been recognized, but the evidence is fragmented and variable. We aim to examine the published literature regarding the association

Full access

HSR24-125: A Narrative Review on Geriatric Assessment and Outcomes in Diffuse Large B-Cell Lymphoma: Differentiating Fit, Frail, and Unfit Patients

Ekaterina Proskuriakova, Iuliia Kovalenko, Chandi Garg, Megan Adams, and Pam G. Khosla

thorough search strategy, developed with a medical research librarian, was used to gather data until July 8, 2023. Inclusion criteria involved DLBCL patient outcomes relative to geriatric assessment scores and selected treatments (curative vs palliative

Full access

HSR23-090: Racial Differences in Outcomes of Osimertinib in Patients With EGFR-Positive Non–Small Cell Lung Cancer in a Real World US Population

Jeffrey Zhong, Jaime Abe Perez, Annie Liang Zhang, Debora Bruno, and Melinda Laine-Hsu

mortality when compared to non-Asian patients with EGFR-positive NSCLC in a real-world US population. Further research is required to determine whether this association stems from a biological or non-biological cause. Table. Outcomes between AANHPI

Full access

CLO20-036: Comparative Outcomes of Patients With Locoregional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated With Definitive Therapy

Cole Friedes, Nick Mai, Wei Fu, Peijin Han, Ranh Voong, and Russell Hales

Background: Although isolated locoregional recurrence (iLR) for non-small cell lung cancer (NSCLC) is relatively common, the optimal therapy for iLR is undefined. It is feasible that patients with iLR may have equal or superior outcomes to patients

Full access

NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia

Neil P. Shah

response levels on outcome. Findings showed that no significant difference was observed for relapse according to depth of molecular response at discontinuation. Data from Mahon et al. 2 Relaxing the threshold, as well as the duration of DMR, has made TKI

Full access

HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study

Ruixuan Jiang, Geoffrey Johnson, Emilie Scherrer, John Kang, Kathleen M. Aguilar, Rohini Singh, and Eric D. Whitman

Background: The aim of this real-world study was to compare clinical outcomes for patients with BRAF-mutant advanced/metastatic melanoma who received first-line (1L) anti-PD1 monotherapy or 1L BRAF/MEK inhibitor therapy, accounting for second